Advertisement

Familial Mediterranean Fever

  • Selcan Demir
  • İlkin Elif Günel
  • Seza ÖzenEmail author
Chapter

Abstract

Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disease which has a high prevalence in the eastern Mediterranean. The typical FMF attack is characterized by fever and polyserositis in the form of abdominal or chest pain or arthritis along with high acute phase reactants. FMF is caused by different mutations in the MEFV gene coding for pyrin. The gain-of-function mutations in the MEFV gene are associated with an exaggerated inflammatory response via an increased production of interleukin-1.

An international group of experts has published the recommendations for the management of FMF. Colchicine is still the mainstay of FMF treatment, and its regular use prevents attacks, controls subclinical inflammation, and decreases the development of amyloidosis which is the most significant complication of FMF. However, a minor proportion of patients can be resistant to colchicine. If colchicine fails, anti-IL-1 therapy is a promising second-line therapy.

Keywords

Familial Mediterranean fever Pyrin Autoinflammatory disease Periodic fever Colchicine Anti-IL-1 agents 

References

  1. 1.
    Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227–53.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797–807.CrossRefGoogle Scholar
  3. 3.
    French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25–31.CrossRefGoogle Scholar
  4. 4.
    Berkun Y, Ben-Chetrit E. Pyrin and cryopyrin--similar domain sequence but opposite inflammatory consequence. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S6–8.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol. 2000;14(3):477–98.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Majeed HA, Rawashdeh M, el-Shanti H, Qubain H, Khuri-Bulos N, Shahin HM. Familial Mediterranean fever in children: the expanded clinical profile. QJM. 1999;92(6):309–18.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991;34(8):973–7.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314(16):1001–5.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Stoffels M, Szperl A, Simon A, Netea MG, Plantinga TS, van Deuren M, et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis. 2014;73(2):455–61.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Giancane G, Ter Haar NM, Wulffraat N, Vastert SJ, Barron K, Hentgen V, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015;74(4):635–41.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 2009;60(6):1851–61.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Shinar Y, Obici L, Aksentijevich I, Bennetts B, Austrup F, Ceccherini I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012;71(10):1599–605.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 2001;9(7):473–83.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Ben-Chetrit E, Lerer I, Malamud E, Domingo C, Abeliovich D. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? Hum Mutat. 2000;15(4):385–6.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Tchernitchko D, Legendre M, Cazeneuve C, Delahaye A, Niel F, Amselem S. The E148Q MEFV allele is not implicated in the development of familial Mediterranean fever. Hum Mutat. 2003;22(4):339–40.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Ozen S, Demirkaya E, Amaryan G, Kone-Paut I, Polat A, Woo P, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis. 2014;73(4):662–7.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9(7):553–5.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Marek-Yagel D, Berkun Y, Padeh S, Abu A, Reznik-Wolf H, Livneh A, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009;60(6):1862–6.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Federici S, Calcagno G, Finetti M, Gallizzi R, Meini A, Vitale A, et al. Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. Ann Rheum Dis. 2012;71(12):1961–5.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45(6):746–50.CrossRefGoogle Scholar
  21. 21.
    Kalyoncu M, Acar BC, Cakar N, Bakkaloglu A, Ozturk S, Dereli E, et al. Are carriers for MEFV mutations “healthy”? Clin Exp Rheumatol. 2006;24(5 Suppl 42):S120–2.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Niemi K, Teirila L, Lappalainen J, Rajamaki K, Baumann MH, Oorni K, et al. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol. 2011;186(11):6119–28.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Atoyan S, Hayrapetyan H, Sarkisian T, Ben-Chetrit E. MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia. Clin Exp Rheumatol. 2016;34(6 Suppl 102):72–6.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Cazeneuve C, Ajrapetyan H, Papin S, Roudot-Thoraval F, Genevieve D, Mndjoyan E, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet. 2000;67(5):1136–43.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Schwabe AD, Peters RS. Familial Mediterranean Fever in Armenians. Analysis of 100 cases. Medicine (Baltimore). 1974;53(6):453–62.CrossRefGoogle Scholar
  26. 26.
    Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 2007;56(5):1706–12.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95(10):3223–31.PubMedPubMedCentralGoogle Scholar
  28. 28.
    de Torre-Minguela C, Mesa Del Castillo P, Pelegrin P. The NLRP3 and pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol. 2017;8:43.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Weinert C, Morger D, Djekic A, Grutter MG, Mittl PR. Crystal structure of TRIM20 C-terminal coiled-coil/B30.2 fragment: implications for the recognition of higher order oligomers. Sci Rep. 2015;5:10819.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol. 2012;12(8):570–80.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Yu JW, Fernandes-Alnemri T, Datta P, Wu J, Juliana C, Solorzano L, et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell. 2007;28(2):214–27.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007;14(8):1457–66.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Hesker PR, Nguyen M, Kovarova M, Ting JP, Koller BH. Genetic loss of murine pyrin, the Familial Mediterranean Fever protein, increases interleukin-1beta levels. PLoS One. 2012;7(11):e51105.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity. 2011;34(5):755–68.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Gavrilin MA, Abdelaziz DH, Mostafa M, Abdulrahman BA, Grandhi J, Akhter A, et al. Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia. J Immunol. 2012;188(7):3469–77.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Xu H, Yang J, Gao W, Li L, Li P, Zhang L, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature. 2014;513(7517):237–41.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17(8):914–21.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Gao W, Yang J, Liu W, Wang Y, Shao F. Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation. Proc Natl Acad Sci U S A. 2016;113(33):E4857–66.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Van Gorp H, Saavedra PH, de Vasconcelos NM, Van Opdenbosch N, Vande Walle L, Matusiak M, et al. Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation. Proc Natl Acad Sci U S A. 2016;113(50):14384–9.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351(9103):659–64.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Gedalia A, Adar A, Gorodischer R. Familial Mediterranean fever in children. J Rheumatol Suppl. 1992;35:1–9.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Brauman A, Gilboa Y. Recurrent pulmonary atelectasis as a manifestation of familial Mediterranean fever. Arch Intern Med. 1987;147(2):378–9.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum. 2001;44(6):1416–9.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z, Sood R, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine. 1998;77(4):268–97.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Ince E, Cakar N, Tekin M, Kendirli T, Ozkaya N, Akar N, et al. Arthritis in children with familial Mediterranean fever. Rheumatol Int. 2002;21(6):213–7.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev. 2012;12(1):31–7.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Langevitz P, Zemer D, Livneh A, Shemer J, Pras M. Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol. 1994;21(9):1708–9.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Majeed HA, Al-Qudah AK, Qubain H, Shahin HM. The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum. 2000;30(2):138–43.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Azizi E, Fisher BK. Cutaneous manifestations of familial Mediterranean fever. Arch Dermatol. 1976;112(3):364–6.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Barzilai A, Langevitz P, Goldberg I, Kopolovic J, Livneh A, Pras M, et al. Erysipelas-like erythema of familial Mediterranean fever: clinicopathologic correlation. J Am Acad Dermatol. 2000;42(5 Pt 1):791–5.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Kees S, Langevitz P, Zemer D, Padeh S, Pras M, Livneh A. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM. 1997;90(10):643–7.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Eshel G, Vinograd I, Barr J, Zemer D. Acute scrotal pain complicating familial Mediterranean fever in children. Br J Surg. 1994;81(6):894–6.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Ben-Chetrit E, Cohen R, Chajek-Shaul T. Familial mediterranean fever and Behcet’s disease--are they associated? J Rheumatol. 2002;29(3):530–4.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Schwartz T, Langevitz P, Zemer D, Gazit E, Pras M, Livneh A. Behcet's disease in Familial Mediterranean fever: characterization of the association between the two diseases. Semin Arthritis Rheum. 2000;29(5):286–95.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Ozdogan H, Arisoy N, Kasapcapur O, Sever L, Caliskan S, Tuzuner N, et al. Vasculitis in familial Mediterranean fever. J Rheumatol. 1997;24(2):323–7.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Ozen S, Ben-Chetrit E, Bakkaloglu A, Gur H, Tinaztepe K, Calguneri M, et al. Polyarteritis nodosa in patients with Familial Mediterranean Fever (FMF): a concomitant disease or a feature of FMF? Semin Arthritis Rheum. 2001;30(4):281–7.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Akpolat T, Akpolat I, Karagoz F, Yilmaz E, Kandemir B, Ozen S. Familial Mediterranean fever and glomerulonephritis and review of the literature. Rheumatol Int. 2004;24(1):43–5.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Said R, Hamzeh Y, Said S, Tarawneh M, al-Khateeb M. Spectrum of renal involvement in familial Mediterranean fever. Kidney Int. 1992;41(2):414–9.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F, et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol. 2003;21(4):509–14.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002;61(1):79–81.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Tunca M, Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN. Acute phase response and evolution of familial Mediterranean fever. Lancet. 1999;353(9162):1415.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Cazeneuve C, Sarkisian T, Pecheux C, Dervichian M, Nedelec B, Reinert P, et al. MEFV-gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. Am J Hum Genet. 1999;65(1):88–97.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum. 2003;48(4):1149–55.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Kone Paut I, Dubuc M, Sportouch J, Minodier P, Garnier JM, Touitou I. Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology. 2000;39(11):1275–9.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Shinar Y, Livneh A, Langevitz P, Zaks N, Aksentijevich I, Koziol DE, et al. Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever. J Rheumatol. 2000;27(7):1703–7.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Blum A, Sohar E. The diagnosis of amyloidosis. Ancillary procedures. Lancet. 1962;1(7232):721–4.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10):1879–85.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Yalcinkaya F, Ozen S, Ozcakar ZB, Aktay N, Cakar N, Duzova A, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology. 2009;48(4):395–8.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Sonmez HE, Batu ED, Ozen S. Familial Mediterranean fever: current perspectives. J Inflamm Res. 2016;9:13–20.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Touitou I, Lesage S, McDermott M, Cuisset L, Hoffman H, Dode C, et al. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat. 2004;24(3):194–8.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Ozen S. Changing concepts in familial Mediterranean fever: is it possible to have an autosomal-recessive disease with only one mutation? Arthritis Rheum. 2009;60(6):1575–7.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Moghaddas F, Llamas R, De Nardo D, Martinez-Banaclocha H, Martinez-Garcia JJ, Mesa-Del-Castillo P, et al. A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever. Ann Rheum Dis. 2017;76:2085.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–51.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287(25):1302.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr. 2012;161(6):1142–6.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004;428(6979):198–202.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516–8.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P. Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther. 2014;95(1):89–97.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    van der Hilst J, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75–80.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533–41.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Bilgen SA, Kilic L, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, et al. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol. 2011;17(7):358–62.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73(12):2168–73.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pediatrics, Division of RheumatologyHacettepe University Faculty of MedicineAnkaraTurkey
  2. 2.Department of PediatricsHacettepe University Faculty of MedicineAnkaraTurkey

Personalised recommendations